Evidence map›Paper›PMID 29423595›Full record

ReviewTargeted oncology2018

Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Mehran Makvandi, Edouard Dupis, Jonathan W Engle, F Meiring Nortier, Michael E Fassbender, Sam Simon, Eva R Birnbaum, Robert W Atcher, Kevin D John, Olivier Rixe and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Targeted oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. EJNMMI radiopharmacy and chemistry · 2025
    Review
  15. It's a match: use of the radionuclide theranostic pairEJNMMI radiopharmacy and chemistry · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mehran MakvandiRadiopharmaceutical Sciences Program, College of Pharmacy, Health Sciences Center, University of New Mexico, MSC09 5360, Albuquerque, NM, 87131-0001, USA.
Edouard DupisExperimental Therapeutics Unit, University of New Mexico Comprehensive Cancer Center, 1210 Camino de Salud, Albuquerque, NM, 87131, USA.
Jonathan W EngleLos Alamos National Laboratory, Los Alamos, NM, USA.
F Meiring NortierLos Alamos National Laboratory, Los Alamos, NM, USA.
Michael E FassbenderLos Alamos National Laboratory, Los Alamos, NM, USA.
Sam SimonRadiopharmaceutical Sciences Program, College of Pharmacy, Health Sciences Center, University of New Mexico, MSC09 5360, Albuquerque, NM, 87131-0001, USA.
Eva R BirnbaumLos Alamos National Laboratory, Los Alamos, NM, USA.
Robert W AtcherRadiopharmaceutical Sciences Program, College of Pharmacy, Health Sciences Center, University of New Mexico, MSC09 5360, Albuquerque, NM, 87131-0001, USA.
Kevin D JohnLos Alamos National Laboratory, Los Alamos, NM, USA.
Olivier RixeExperimental Therapeutics Unit, University of New Mexico Comprehensive Cancer Center, 1210 Camino de Salud, Albuquerque, NM, 87131, USA. orixe@salud.unm.edu.
Jeffrey P NorenbergRadiopharmaceutical Sciences Program, College of Pharmacy, Health Sciences Center, University of New Mexico, MSC09 5360, Albuquerque, NM, 87131-0001, USA. jnorenberg@salud.unm.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alpha-emitters are radionuclides that decay through the emission of high linear energy transfer α-particles and possess favorable pharmacologic profiles for cancer treatment. When coupled with monoclonal antibodies, peptides, small molecules, or nanoparticles, the excellent cytotoxic capability of α-particle emissions has generated a strong interest in exploring targeted α-therapy in the pre-clinical setting and more recently in clinical trials in oncology. Multiple obstacles have been overcome by researchers and clinicians to accelerate the development of targeted α-therapies, especially with the recent improvement in isotope production and purification, but also with the development of innovative strategies for optimized targeting. Numerous studies have demonstrated the in vitro and in vivo efficacy of the targeted α-therapy. Radium-223 (

Indexed as

Alpha ParticlesHumansNeoplasms

Identifiers

PMID29423595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.